B7-2 Antigen

A costimulatory ligand glycoprotein that contains a C2 and V-type IMMUNOGLOBULIN DOMAIN. It is expressed by ANTIGEN-PRESENTING CELLS and binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.

Also Known As:

Networked: 25 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bluestone, Jeffrey A: 2 articles (09/2013 - 11/2005)
2.	Bour-Jordan, Hélène: 2 articles (09/2013 - 11/2005)
3.	Thompson, Heather L: 2 articles (09/2013 - 11/2005)
4.	Gosik, Krzysztof: 1 article (01/2022)
5.	Grywalska, Ewelina: 1 article (01/2022)
6.	Góźdź, Stanisław: 1 article (01/2022)
7.	Hymos, Anna: 1 article (01/2022)
8.	Kwaśniewski, Wojciech: 1 article (01/2022)
9.	Ludian, Jarosław: 1 article (01/2022)
10.	Mielnik, Michał: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 03/01/1996 - "Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule." 05/20/2004 - "To determine whether up-regulated expression of the costimulatory molecule, B7-2, leads to more effective anti-tumor immunity in vivo, the A20 murine model of B-cell lymphoma was used. " 05/20/2004 - "The costimulatory molecule, B7-2, is expressed by various lymphomas, but this level of expression is not sufficient to generate effective anti-tumor immunity in vivo. " 08/01/2003 - "Analysis of the annotation of the most significant genes revealed the relevance of critical genes and pathways during bladder cancer progression, including the overexpression of oncogenic genes such as DEK in superficial tumors or immune response genes such as Cd86 antigen in invasive disease. " 04/15/1999 - "A20 is a B cell lymphoma that constitutively expresses the costimulatory molecule B7-2 yet grows readily as a tumor in syngeneic BALB/c mice. "
2.	Infections 01/01/2022 - "Our earlier immunohistochemical studies revealed that the organisms were markedly labeled with the CD86 antigen in cutaneous lesions brought on by infection. " 05/01/2000 - "Here the authors investigated class I and class II antigens and B7-1 and B7-2 costimulatory molecule expression in human A549 pulmonary epithelial cells and primary bronchial epithelial cells (HBECs) at baseline and after rhinovirus infection. "
3.	Allergic Rhinitis 10/01/2019 - "The aim of the present study was to investigate the expression and role of the co‑stimulatory molecule T‑lymphocyte activation antigen CD86 (CD86) in dendritic cells (DCs) from the peripheral blood of patients with allergic rhinitis (AR) compared with those from healthy individuals. "
4.	Necrosis 01/01/1999 - "Further study to find the mechanism underlying this revealed that there was up-regulation of major histocompatibility complex (MHC) class II, CD86 antigens on DC and increased production of interleukin-12 (IL-12) by DC and of IL-2, and tumour necrosis factor-alpha (TNF-alpha) in DC/T-cell cultures when vaccine containing HBsAg was injected in HBV-Tg with potent DC function but not in HBV-Tg with poor DC function. "
5.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/01/2018 - "Spontaneous autoimmune peripheral polyneuropathy (SAPP) is a mouse model of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in non-obese diabetic (NOD) mice null for costimulatory molecule, B7-2 gene (B7-2-/-). " 12/15/2008 - "Elimination of the costimulatory molecule B7-2 prevents autoimmune diabetes in NOD mice, but leads to the development of a spontaneous autoimmune polyneuropathy (SAP), which resembles the human disease chronic inflammatory demyelinating polyneuropathy (CIDP). " 11/01/2005 - "NOD mice deficient for the costimulatory molecule B7-2 (NOD-B7-2KO mice) are protected from autoimmune diabetes but develop a spontaneous autoimmune peripheral neuropathy that resembles human diseases Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. "

Related Drugs and Biologics

1.	Melphalan (Alkeran)
2.	galiximab
3.	Vaccines
4.	Hepatitis B Surface Antigens (HBsAg)
5.	Interleukin-12 (IL 12)
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Interleukin-2 (IL2)
8.	Antigens
9.	DNA Vaccines
10.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

Related Therapies and Procedures

1.	Intramuscular Injections